Assessing Ocular Surface Changes After Changing Glaucoma Medications
hypothesis: changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.
Monotherapy With Xalatan From 1 to 18 Months
Ocular Surface Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.|
- Change in Signs and Symptoms of Ocular Surface Disease [ Time Frame: 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||November 2007|
|Study Completion Date:||August 2011|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be record at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.
|United States, Colorado|
|Rocky Mountain Lions Eye Institute|
|Aurora, Colorado, United States, 80045-0510|
|Principal Investigator:||Malik Y Kahook, M.D.||Rocky mountain Lions Eye Institute|